| Recruiting | 1/2 | 104 | Europe, RoW | DYNE-101, Placebo | Dyne Therapeutics, Dyne Therapeutics, Inc | Myotonic Dystrophy Type 1 (DM1) | 07/26 | 07/26 | | |
NCT03981575: Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) |
|
|
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | Virginia Commonwealth University, University of Rochester, Stanford University, Ohio State University, University of Florida, University of Iowa, Ludwig-Maximilians - University of Munich, Fondazione Serena Onlus - Centro Clinico NeMO Milano, The Methodist Hospital Research Institute, Radboud University Medical Center, University College London Hospitals, University of California, Los Angeles | Myotonic Dystrophy 1, DM1 | 10/26 | 12/26 | | |
